Detection of most gene rearrangements requires large-scale screening of patients during trials. A better alternative to Next Generation Sequencing, PanelChip® is cost-effective, customizable and simple to use. Fast turnaround time, flexible sample throughput and the capability to analyze poor quality/low concentration samples make clinical trials much more efficient.
Working with various pharmaceutical companies, Quark Biosciences has customized PanelChip® to detect all fusion transcripts to a single gene, such as ROS1 or NTRK. Among the latest examples is a MET panel capable of detecting all MET rearrangement and amplification.
Quark Biosciences is dedicated to providing the highest quality and standard (ISO13485/GMP) for the development of IVD-grade assays.Our proprietary technology PanelChip® is an ideal platform for companion and complementary diagnostics, with the following advantages:
Utilizing our proprietary dqPCR functionality, we have developed MoDEL™, an ultra-sensitive liquid biopsy assay to detect EGFR T790M mutation, allowing clinician to provide corrective treatment in a timely fashion.Learn more
miRNAs are potential diagnostics and prognostics cancer biomarkers. QuarkBio has built the most comprehensive miRNA-disease association database, miDatabase™, and developed the mirSCAN PanelChip® with disease-relevant miRNA biomarkers. Using mirSCAN, we have demonstrated the clinical utility of circulating miRNA biomarkers in the early detection of HNSCC cancer and the response prediction of immunotherapy. Accurate reproducibility and repeatability make PanelChip® a suitable platform for the discovery of expression biomarkers.